Viagra, Cialis and Levitra Use Shows 84% Increase Melanoma Skin Cancer Risk

Viagra increases Melanoma risks like these in men by over 8 times.

The following is a study linking Viagra, Cialis and Levitra to Increased Melanoma Skin Cancer in Men

Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study

Contact an Attorney!
If you or a loved one has been diagnosed with Melanoma Skin Cancer and has taken Viagra or another Sildenafil based drug, use the form below to find out what your options are.

Your Name (required)

Your Email (required)

Your Phone Number (required)

When were you diagnosed with Melanoma?

Details on your Viagra use and other information you want to provide.

Information you provide will be directed to attorneys who specialize in tort, class action and personal injury lawsuits. The more details you provide the better the service will be. Your submission is your agreement to the terms and conditions for using this site as seen in the footer below.

Authors

1) Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts2Department of Dermatology, Rhode Island Hospital, Warren Alpert Medical School, Brown University, Providence.
2) Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Department of Dermatology, Rhode Island Hospital, Warren Alpert Medical School, Brown University, Providence Channing Division of Network Medicine, Depa.
3) Department of Dermatology, Massachusetts General Hospital, Boston5Graduate Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts.
4) Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School

IMPORTANCE:

The RAS/RAF/mitogen-activated protein kinase and extracellular signal-regulated kinase (ERK) kinase/ERK cascade plays a crucial role in melanoma cell proliferation and survival. Sildenafil citrate (Viagra, Cialis and Levitra) is a phosphodiesterase (PDE) 5A inhibitor commonly used for erectile dysfunction. Recent studies have shown that BRAF activation down-regulates PDE5A levels, and low PDE5A expression by BRAF activation or sildenafil use increases the invasiveness of melanoma cells, which raises the possible adverse effect of sildenafil use on melanoma risk.

OBJECTIVE:

To evaluate the association between sildenafil use and risk of incident melanoma among men in the United States.

DESIGN, SETTING, AND PARTICIPANTS:

Our study is a prospective cohort study. In 2000, participants in the Health Professionals’ Follow-up Study were questioned regarding sildenafil use for erectile dysfunction. Participants who reported cancers at baseline were excluded. A total of 25,848 men remained in the analysis.

MAIN OUTCOMES AND MEASURES:

The incidence of skin cancers, including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), was obtained in the self-reported questionnaires biennially. The diagnosis of melanoma and SCC was pathologically confirmed.

RESULTS:

We identified 142 melanoma, 580 SCC, and 3030 BCC cases during follow-up (2000-2010). Recent sildenafil use at baseline was significantly associated with an increased risk of subsequent melanoma with a multivariate-adjusted hazard ratio (HR) of 1.84 (95% CI, 1.04-3.22). In contrast, we did not observe an increase in risk of SCC (HR, 0.84; 95% CI, 0.59-1.20) or BCC (1.08; 0.93-1.25) associated with sildenafil use. Moreover, erectile function itself was not associated with an altered risk of melanoma. Ever use of sildenafil was also associated with a higher risk of melanoma (HR, 1.92; 95% CI, 1.14-3.22). A secondary analysis excluding those reporting major chronic diseases at baseline did not appreciably change the findings; the HR of melanoma was 2.24 (95% CI, 1.05-4.78) for sildenafil use at baseline and 2.77 (1.32-5.85) for ever use.

CONCLUSIONS AND RELEVANCE:

Sildenafil use may be associated with an increased risk of developing melanoma. Although this study is insufficient to alter clinical recommendations, we support a need for continued investigation of this association.

In 2014, about 76,100 new melanomas will be diagnosed, and an estimated 9710 persons will die (about 6470 men and 3240 women).1 Patients with melanoma in situ, stage 0, have a 5-year survival rate of 99% when treated with excision, whereas those with melanoma limited to the skin and with a tumor thickness of 2.01 to 4.0 mm, stage II B, have a 5-year survival rate of about 57%. Patients with metastatic melanoma, stage IV, have a 5-year survival rate of 15% to 20%. Despite newly available targeted agents, systemic therapies rarely lead to cures. These sizable survival differences illustrate the need for early detection of melanoma; early detection of primary melanomas followed by surgical excision remains critical.

For more information on the link between Viagra, Cialis or Levitra and melanoma skin cancer, click here: Viagra Melanoma Attorneys

Comments are closed.